Friday, 21 Sep 2018

You are here

IL-18 Binding Protein Effective in Adult-Onset Still's Disease

Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).

The treatment of Still's disease has been revolutionized by the observation that this inflammasomopathy can be more effectively managed by inhibitors of IL-1 and IL-6.  But the same mechanisms driving excess IL-1 production and excessive caspase activity are mirrored by IL-18. 

They enrolled 21 adults with AOSD plus fever or or elevated C-reactive protein (CRP) levels and were treated with tadekinig alfa 80 mg (10 patients)  or 160 mg (13 patients) subcutaneously three times per week for 12 weeks.

By week 3, half of those treated with either 80 mg or 160 mg achieved the predefined response criteria.

They found 155 treatment-emerging AEs were recorded, most of which were mild, resolved and one-third were were considered related to the study drug.  There were 3 serious AEs occurred, one possibly related to treatment (toxic optic neuropathy).

These early results suggest and acceptable safety profile and good efficacy and warrants further controlled trial investigation in AOSD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Treat-to-Target in RA: No Increase in AEs

Implementing a treat-to-target approach for the care of rheumatoid arthritis (RA) did not result in an increase in adverse events or resource use, a post-hoc analysis of a randomized trial showed.

Mediterranean Diet Reduces Risk of Rheumatoid Arthritis

High adherence to a Mediterranean diet appears to be associated with a lower risk of rheumatoid arthritis (RA), especially in men and those who are seropositive, according to a study published in Arthritis Research & Therapy.

Early Exposure to Passive Smoke May Up Risk for RA Later in Life

Exposure to second-hand smoke during childhood was associated with an increased risk for developing rheumatoid arthritis (RA) later in life, researchers said.

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).